Summary
Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm.
In the Experimental Arm, for the first 3 cycles, participants receive a coformulation of pembrolizumab/vibostolimab via intravenous (IV) infusion on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3.
Participants then receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to ~14 months). Cycles 1-20 are 21-day cycles.
In the Active Comparator Arm, for the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3.
Following cCRT, participants receive durvalumab every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.
In both arms, Investigator's choice of chemotherapy may be:
- cisplatin and pemetrexed for non-squamous histology only; or
- cisplatin and etoposide; or
- carboplatin and paclitaxel.
Conditions
This trial is treating people with unresectable, locally advanced, stage III non-small cell lung cancer